Antiplatelet Therapy and Lumbar Transforaminal Epidural Steroid Injections

  • Registration Closed

Myth: Antiplatelet therapy must be discontinued prior to all lumbar transforaminal epidural steroid injections.

Learn about the facts surrounding this myth and the best practices to support safe performance of interventional pain procedures in your practice. 

Each participant will read the FactFinder and will answer post-test questions to earn continuing medical education (CME) credits.  

Authors  
David C. Miller, MD, MA; Clark Smith, MD, MPH; and Zachary L. McCormick, MD on behalf of the Spine Intervention Society’s Patient Safety Committee

Copyright 
Materials presented in this activity have been made available by the Spine Intervention Society for educational purposes only. We reserve all rights to such material.

Educational Objectives  
Upon completion of this activity, participants should be able to:

  • Identify best practices to ensure patient safety during interventional spine procedures
  • Cite the evidentiary basis for risk mitigation strategies in the safe performance of interventional pain procedures

Author Disclosures Information  
RELEVANT FINANCIAL RELATIONSHIPS WITH ACCME-DEFINED COMMERCIAL INTERESTS
David C. Miller, MD
Nothing to disclose

Clark C. Smith, MD, MPH 
Nothing to disclose 

Zachary L. McCormick, MD
Nothing to disclose

OTHER DISCLOSURES
David C. Miller, MD 
Nothing to disclose

Clark C. Smith, MD, MPH 
Nothing to disclose

Zachary L. McCormick, MD
Position in healthcare association/society: SIS, NASS, AAPM, Pacific Spine and Pain Society. 
Service as a consultant, expert witness: Medicolegal.
Grant and research support: Avanos, EpiMed, Skaggs Research Foundation
Travel Expenses: SIS Board of Directors. Speaker, American Academy of Pain Medicine; Speaker North American Spine Society.

References  
References are provided within the FactFinder.

Accreditation Statement  
The Spine Intervention Society (SIS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  

Credit Designation Statement  
SIS designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Date of Activity Release: 11/02/2020  
Date of Activity Expiration: 11/01/2023

Components visible upon registration.